JP2004500110A5 - - Google Patents

Download PDF

Info

Publication number
JP2004500110A5
JP2004500110A5 JP2001570286A JP2001570286A JP2004500110A5 JP 2004500110 A5 JP2004500110 A5 JP 2004500110A5 JP 2001570286 A JP2001570286 A JP 2001570286A JP 2001570286 A JP2001570286 A JP 2001570286A JP 2004500110 A5 JP2004500110 A5 JP 2004500110A5
Authority
JP
Japan
Prior art keywords
hsa
cells
polypeptide
human
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001570286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004500110A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/040390 external-priority patent/WO2001072325A1/en
Publication of JP2004500110A publication Critical patent/JP2004500110A/ja
Publication of JP2004500110A5 publication Critical patent/JP2004500110A5/ja
Pending legal-status Critical Current

Links

Images

JP2001570286A 2000-03-29 2001-03-29 自己反応性t細胞による組織破壊をブロックする方法 Pending JP2004500110A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19281400P 2000-03-29 2000-03-29
PCT/US2001/040390 WO2001072325A1 (en) 2000-03-29 2001-03-29 Methods of blocking tissue destruction by autoreactive t cells

Publications (2)

Publication Number Publication Date
JP2004500110A JP2004500110A (ja) 2004-01-08
JP2004500110A5 true JP2004500110A5 (https=) 2008-05-15

Family

ID=22711138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001570286A Pending JP2004500110A (ja) 2000-03-29 2001-03-29 自己反応性t細胞による組織破壊をブロックする方法

Country Status (8)

Country Link
EP (1) EP1267909B1 (https=)
JP (1) JP2004500110A (https=)
AT (1) ATE475428T1 (https=)
AU (2) AU2001259792B2 (https=)
CA (1) CA2404340C (https=)
DE (1) DE60142684D1 (https=)
DK (1) DK1267909T3 (https=)
WO (1) WO2001072325A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030106084A1 (en) 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
US8808697B2 (en) * 2010-04-28 2014-08-19 Oncoimmune, Inc. Methods of use of soluble CD24 for therapy of rheumatoid arthritis
US20150140019A1 (en) * 2012-07-13 2015-05-21 The Trustees Of The University Of Pennsylvania Compositions and Methods for Regulating CAR T Cells
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
SG10201913782UA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
US20190119353A1 (en) * 2014-11-06 2019-04-25 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
HRP20201651T1 (hr) * 2015-05-07 2020-12-25 Oncoimmune, Inc. Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola
EP3334449B1 (en) * 2015-08-10 2021-09-29 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using cd24
EP3411062B1 (en) * 2016-02-02 2020-11-25 Oncoimmune Inc. Use of cd24 proteins for treating leptin-deficient conditions
JP2020510020A (ja) * 2017-03-07 2020-04-02 オンコイミューン, インコーポレイテッド 全身性エリテマトーデスを治療するために可溶性cd24を使用する方法
EP3624838B1 (en) * 2017-05-15 2023-01-25 Oncoimmune, Inc. Methods of use of soluble cd24 for neuroprotection and remyelination
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途

Similar Documents

Publication Publication Date Title
US12319741B2 (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
AU2018209012B2 (en) BCMA-targeting antibody and use thereof
US6737057B1 (en) Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
EP1292621B1 (en) Compositions for treating autoimmune disease
HUE029789T2 (en) Trimer OX40 Immunoglobulin Fusion Protein and Methods of Application
JPH09509826A (ja) 活性化cd4▲上+▼t細胞の表層上のレセプターに対するリガンド(act−4−l)
JP2002514895A (ja) ブタ細胞相互作用タンパク質
JP2009240311A (ja) 活性化されたt細胞の表面上のレセプタ:act−4
TW200823235A (en) Prophylactic and therapeutic agent for cancers
KR102296416B1 (ko) 항-세라마이드 항체
JP2012513761A (ja) 初期の眼内リンパ腫の治療に対する抗cd20抗体の使用方法
CA2404340C (en) Methods of blocking tissue destruction by autoreactive t cells
US20090280132A1 (en) Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease
JP2004500110A5 (https=)
KR101985863B1 (ko) ADCC 향상을 위한 항체 Fc 변이체
US20030106084A1 (en) Methods of blocking tissue destruction by autoreactive T cells
AU2001259792A1 (en) Methods of blocking tissue destruction by autoreactive T cells
US20070218053A1 (en) Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease
US20030095966A1 (en) Method of blocking tissue destruction by autoreactive T cells
US20040210037A1 (en) Targeted MHC class I alpha3 vaccine delivery systems
WO2007101254A2 (en) Compositions and methods for the treatment of immune system disorders
RU2799655C2 (ru) Антитело, нацеленное на всма, и его применение